{"corpus_id":12040695,"paper_sha":"cab78dd4a7ba077824067d7994a28c480d0847f0","doi":"10.1016/S0954-6111(99)90058-6","arxiv_id":null,"pmid":10653054,"pmcid":null,"mag_id":2018402822,"dblp_id":null,"acl_id":null,"title":"Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD.","year":1999,"publication_date":"1999-12-01","venue":"Respiratory Medicine","journal":{"name":"Respiratory medicine","pages":"\n          909-11\n        ","volume":"93 12"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle","ClinicalTrial"],"pubmed_pub_types":["Clinical Trial","Journal Article","Randomized Controlled Trial"],"s2_fields_of_study":["Medicine"],"reference_count":15,"citation_count":16,"influential_citation_count":0,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Administration, Inhalation","mj":false,"ui":"D000280"},{"d":"Adrenergic beta-Agonists","mj":false,"qs":[{"q":"administration & dosage","mj":true,"ui":"Q000008"}],"ui":"D000318"},{"d":"Bronchi","mj":false,"qs":[{"q":"drug effects","mj":true,"ui":"Q000187"}],"ui":"D001980"},{"d":"Bronchodilator Agents","mj":false,"qs":[{"q":"administration & dosage","mj":true,"ui":"Q000008"}],"ui":"D001993"},{"d":"Cross-Over Studies","mj":false,"ui":"D018592"},{"d":"Dose-Response Relationship, Drug","mj":false,"ui":"D004305"},{"d":"Drug Therapy, Combination","mj":false,"ui":"D004359"},{"d":"Ethanolamines","mj":false,"qs":[{"q":"administration & dosage","mj":true,"ui":"Q000008"}],"ui":"D004983"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Forced Expiratory Volume","mj":false,"ui":"D005541"},{"d":"Formoterol Fumarate","mj":false,"ui":"D000068759"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Lung Diseases, Obstructive","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"physiopathology","mj":false,"ui":"Q000503"}],"ui":"D008173"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Parasympatholytics","mj":false,"qs":[{"q":"administration & dosage","mj":true,"ui":"Q000008"}],"ui":"D010276"},{"d":"Scopolamine Derivatives","mj":false,"qs":[{"q":"administration & dosage","mj":true,"ui":"Q000008"}],"ui":"D012602"},{"d":"Single-Blind Method","mj":false,"ui":"D016037"}],"chemicals":[{"n":"Adrenergic beta-Agonists","ui":"D000318","reg":"0"},{"n":"Bronchodilator Agents","ui":"D001993","reg":"0"},{"n":"Ethanolamines","ui":"D004983","reg":"0"},{"n":"Parasympatholytics","ui":"D010276","reg":"0"},{"n":"Scopolamine Derivatives","ui":"D012602","reg":"0"},{"n":"oxitropium","ui":"C017590","reg":"8G15T83E6I"},{"n":"Formoterol Fumarate","ui":"D000068759","reg":"W34SHF8J2K"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"We examined the influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in patients with partially reversible stable COPD. Twenty outpatients inhaled one or two puffs of formoterol (12 microg puff(-1)), or placebo. Two hours after inhalation, a dose-response curve to inhaled oxitropium bromide (100 microg puff(-1)) or placebo was constructed using one puff, one puff, two puffs and two puffs, for a total cumulative dose of 600 microg oxitropium bromide. Doses were given at 20-min intervals and measurements made 15 min after each dose. On six separate days, all patients received one of the following: (1) formoterol 12 microg + oxitropium bromide 600 microg, (2) formoterol 12 microg + placebo, (3) formoterol 24 microg + oxitropium bromide 600 microg, (4) formoterol 24 microg + placebo, (5) placebo + oxitropium bromide 600 microg, or (6) placebo + placebo. Both formoterol 12 microg and 24 microg induced a good bronchodilation (formoterol 12 microg, 0.19-0.20 l; formoterol 24 microg 0.22-0.24 l). The dose-response curve of oxitropium, but not placebo, showed an evident increase in FEV1, with a further significant increase of respectively 0.087 l and 0.082 l after the formoterol 12 microg and formoterol 24 microg pre-treatment. This study shows that improved pulmonary function in patients with stable COPD may be achieved by adding oxitropium 400-600 microg to formoterol. There is not much difference in bronchodilation between combining oxitropium with formoterol 12 microg or 24 microg. In any case, formoterol 24 microg alone seems sufficient to achieve the same bronchodilation induced by oxitropium 600 microg alone in most patients.","claims":[{"public_id":"cl_ef8ebe1cb0211079f4de0d25333d9fcb","status":"active","text":"Adding oxitropium bromide 400-600 microg to formoterol can further improve pulmonary function in patients with stable COPD.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_ef8ebe1cb0211079f4de0d25333d9fcb"},{"public_id":"cl_8cf341caa9bc54ecd389c1f82c0999da","status":"active","text":"Formoterol 24 microg alone appears sufficient to achieve bronchodilation comparable to oxitropium bromide 600 microg alone in most patients.","confidence":0.91,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_8cf341caa9bc54ecd389c1f82c0999da"},{"public_id":"cl_ce521d7a211ec3892879fd010b4ab4ac","status":"active","text":"Formoterol pre-treatment increased the FEV1 response to oxitropium bromide by 0.087 l after 12 microg formoterol and by 0.082 l after 24 microg formoterol.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_ce521d7a211ec3892879fd010b4ab4ac"},{"public_id":"cl_bf50b1f271e43e0fb00aa964b92e8f49","status":"active","text":"Oxitropium bromide produced an evident increase in FEV1, whereas placebo did not show the same dose-response effect.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_bf50b1f271e43e0fb00aa964b92e8f49"},{"public_id":"cl_f488b6fe07ac028b16e41c97c7a25871","status":"active","text":"There is little difference in bronchodilation between combining oxitropium bromide with formoterol 12 microg or with formoterol 24 microg.","confidence":0.9,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_f488b6fe07ac028b16e41c97c7a25871"}],"concepts":[{"public_id":"co_296830f91ba346cec13a7ba35653dcca","status":"active","name":"pulmonary function","description":"The functional performance of the lungs as assessed by spirometric response.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_296830f91ba346cec13a7ba35653dcca"},{"public_id":"co_40db13792edd35b24f1e49f450a2f98a","status":"active","name":"stable COPD","description":"Chronic obstructive pulmonary disease in a stable outpatient state with partial reversibility.","types":["condition"],"aliases":["COPD"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_40db13792edd35b24f1e49f450a2f98a"},{"public_id":"co_49c3cd4935c3ca488e9c5e0c5a871b07","status":"active","name":"placebo","description":"An inactive comparator used to control for non-drug effects in the treatment arms.","types":["control"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_49c3cd4935c3ca488e9c5e0c5a871b07"},{"public_id":"co_5cef401aef331a93197c19f434ee24d3","status":"active","name":"bronchodilation","description":"Widening of the airways measured as improvement in lung function after inhaled treatment.","types":["physiological response"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5cef401aef331a93197c19f434ee24d3"},{"public_id":"co_610695b09cc476a5a8b7e3f2e6468a3f","status":"active","name":"partially reversible stable COPD","description":"A subgroup of stable COPD patients with some reversibility of airflow obstruction.","types":["patient population"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_610695b09cc476a5a8b7e3f2e6468a3f"},{"public_id":"co_a25b1039f12e004d259f4fc2856288a8","status":"active","name":"formoterol","description":"An inhaled long-acting beta2-agonist bronchodilator used as pre-treatment in the study.","types":["drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a25b1039f12e004d259f4fc2856288a8"},{"public_id":"co_c1793a4bc594b8e0a010c298843e6ece","status":"active","name":"FEV1","description":"Forced expiratory volume in one second, a measure of lung function and bronchodilator response.","types":["outcome measure"],"aliases":["forced expiratory volume in one second"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c1793a4bc594b8e0a010c298843e6ece"},{"public_id":"co_c89033f66affda4ebdb44fd046bbec8f","status":"active","name":"oxitropium bromide","description":"An inhaled anticholinergic bronchodilator used in the dose-response comparisons.","types":["drug"],"aliases":["oxitropium"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c89033f66affda4ebdb44fd046bbec8f"},{"public_id":"co_ffa0b52bb22fbea35f1b05cba03569db","status":"active","name":"dose-response curve","description":"The relationship between increasing inhaled oxitropium bromide dose and measured lung function response.","types":["measurement"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ffa0b52bb22fbea35f1b05cba03569db"}],"external_ids":{"DOI":"10.1016/S0954-6111(99)90058-6","ArXiv":null,"PubMed":10653054,"PubMedCentral":null,"MAG":2018402822,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/12040695","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":635785,"paper_uid":"1031a36f-63dd-4b0c-a5e8-66b41707ef5e","canonical_identity":{"paper_id":635785,"paper_uid":"1031a36f-63dd-4b0c-a5e8-66b41707ef5e","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/12040695"}